Long‐acting recombinant factor IX Fc fusion protein ( rFIXF c) for perioperative management of subjects with haemophilia B in the phase 3 B‐LONG study-Reference-Cited by-同舟云学术

Long‐acting recombinant factor IX Fc fusion protein ( rFIXF c) for perioperative management of subjects with haemophilia B in the phase 3 B‐LONG study

Published:2014-09-11 Issue:1 Volume:168 Page:124-134
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Powell Jerry S.¹,Apte Shashikant²,Chambost Hervé³,Hermans Cedric⁴,Jackson Shannon⁵,Josephson Neil C.⁶,Mahlangu Johnny N.⁷,Ozelo Margareth C.⁸,Peerlinck Kathelijne⁹,Pasi John¹⁰,Perry David¹¹,Ragni Margaret V.¹²,Wang Xuefeng¹³,Jiang Haiyan¹⁴,Li Shuanglian¹⁴,Cristiano Lynda M.¹⁴,Innes Alison¹⁴,Nugent Karen¹⁴,Brennan Aoife¹⁴,Luk Alvin¹⁴,Allen Geoffrey¹⁴,Pierce Glenn F.¹⁴,Robinson Brian¹⁴

Affiliation:

1. University of California Davis Sacramento CA USA

2. Department of Haematology Sahyadri Hospital Mahara India

3. CTH Service d'Hématologie Pédiatrique Hopital d'Enfants La Timone APHM Aix Marseille Université Marseille France

4. Hématologie Cliniques Universitaires Saint‐Luc Bruxelles Belgium

5. Hemophilia Program of BC – Adult Division St Paul's Hospital Vancouver Canada

6. Puget Sound Blood Center Seattle WA USA

7. Haemophilia Comprehensive Care Centre University of the Witwatersrand NHLS and Johannesburg Hospital Johannesburg South Africa

8. INCT do Sangue Hemocentro UNICAMP Campinas Brazil

9. Bleeding and Vascular Disorders University Hospital Gasthuisberg Leuven Belgium

10. Barts and the London Comprehensive Care Centre LondonUK

11. Addenbrooke's Hospital Cambridge UK

12. University of Pittsburgh and the Hemophilia Center of Western Pennsylvania Pittsburgh PA USA

13. Department of Haematology Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai China

14. Biogen Idec Cambridge MA USA

Funder

Biogen Idec

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.13112

Reference17 articles.

1. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX

2. Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B

3. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations

4. Overview of the human pharmacokinetics of recombinant activated factor VII

5. Evaluation of factor VIII pharmacokinetics in hemophilia-A subjects undergoing surgery and description of a nomogram for dosing calculations

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis;Research and Practice in Thrombosis and Haemostasis;2023-08

2. Managing Relevant Clinical Conditions of Hemophilia A/B Patients;Hematology Reports;2023-06-07

3. Hemostatic cover in orthopedic surgery;Blood Coagulation & Fibrinolysis;2023-06

4. Eftrenonacog Alfa: A Review in Haemophilia B;Drugs;2023-04-21

5. Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies;Research and Practice in Thrombosis and Haemostasis;2022-07